Day: 30 11 月, 2024

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the "National Reimbursement Drug List (2024)" (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. This milestone signifies a breakthrough in advancing the standardization of IgAN treatment and improving accessibility and affordability, offering hope for millions of IgAN patients in China. NEFECON(R) has been prescribed in mainland China since May this year and has been approved in Macau, Hong Kong, Taiwan, China, South Korea and in Singapore under the trade name Nefegan(R).NEFECON(R) is the first ever treatment for IgAN to receive full approval from the U.S. Food and Drug Administration (FDA) and the first non-oncology therapeutic to receive breakthrough therapy designation in China by the China National Medical Products Administration (NMPA), underscoring its globally leading position and exceptional clinical value. Recently, at the 2024 American Society of Nephrology (ASN) Annual Meeting, data from the open-label extension (OLE) phase of the NefIgArd Phase 3 trial demonstrated that patients undergoing a second course of NEFECON(R) treatment experienced similar benefits in estimated glomerular filtration rate (eGFR) preservation and proteinuria reduction as observed after the initial treatment, with good tolerance. These findings further validate the feasibility and efficacy of long-term treatment strategies, aligning with recommendations from the "KDIGO 2024 Clinical Practice Guideline for The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV)", highlighting NEFECON(R)'s innovation and clinical value in IgAN treatment. NEFECON(R) was also listed as the only treatment proven to reduce the levels of pathogenic forms of IgA and IgA immune complexes.IgAN is highly prevalent in Asia and is one of the main causes of kidney failure in young adults in China. Statistics show that with approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand. Since NEFECON(R)'s first prescription was issued in Mainland China in May 2024, the product has demonstrated strong market performance. According to Everest Medicines' interim report, NEFECON(R) achieved RMB1.673 billion in sales within its first month, reflecting widespread recognition of its therapeutic benefits and the significant demand for innovative therapies among Chinese patients.With NEFECON(R)'s successful inclusion in the NRDL, its accessibility and coverage in China are expected to increase significantly, driving sustained and robust commercial revenue growth for Everest Medicines. This milestone not only strengthens the company's leadership in nephrology but also injects new momentum into optimizing resource allocation and promoting synergistic development. As reimbursement coverage leads to expanded market penetration, this development is poised to be a key catalyst in unlocking the full value of the company's core products, further accelerating the reevaluation of its market potential.NEFECON(R) included in the NRDL is a testament to Everest Medicines' differentiated commercial strategy. Another core product, XERAVA(R) (eravacycline) is the world's first fluorocycline antibiotic for the treatment of complicated intra-abdominal infections, continues to excel in the field of complicated intra-abdominal infections. According to the recently released final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", the drug demonstrated an impressive overall treatment effectiveness rate of 90.1%, further affirming its clinical value and safety. As of the first half of 2024, XERAVA(R) achieved cumulative sales of RMB2.33 billion, underscoring its strong market acceptance and potential.In the autoimmune disease portfolio, VELSIPITY(R) continues to make steady progress in its commercialization journey. In October, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) received approval from the Guangdong Provincial Medical Products Administration and is now available for use in three designated medical institutions within the Greater Bay Area. Earlier this year, VELSIPITY(R) was also approved for use in Macau and Singapore. In addition, Everest Medicines recently submitted a new drug application (NDA) for VELSIPITY(R) in Hong Kong and plans to submit an NDA in Mainland China by the end of the year. As Everest Medicines' third commercialized product, VELSIPITY(R) is poised to become a key growth driver, with significant market potential expected to unfold as its adoption expands further.Everest Medicines continues to make significant strides in innovative R&D, with its proprietary mRNA development platform now fully localized. The company's first personalized mRNA cancer vaccine, EVM16, has Initiated an Investigator-Initiated Clinical Trial (IIT). Additionally, EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor being developed globally for the treatment of renal diseases, marks another important advancement. Everest Medicines will host an investor call on December 4th to discuss the results of the Phase 1b/2a clinical study of EVER001 in primary membranous nephropathy, highlighting its potential to drive future growth.Driven by the inclusion of NEFECON(R) in the NRDL and the continued progress of its core pipeline, Everest Medicines' business model demonstrates its resilience and strength. The company remains steadfast in fulfilling its commitments to investors while strengthening market confidence in its innovation and long-term growth potential. With a diversified focus on renal, infectious, and autoimmune diseases, Everest Medicines is harnessing its robust commercialization platform to fuel growth, steadily advancing toward its vision of becoming Asia's leading global biopharmaceutical company. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年11月29日 - (亚太商讯 via SeaPRwire.com) - 据星岛日报报道，自9月份以来，港股IPO市场持续回暖，大型IPO接连涌现。于11月27日港股上市的顺丰控股股份有限公司（「顺丰控股」，股份代号：6936.HK）也是其中之一，并成为港股市场最大的物流领域上市企业。本次IPO，公司计划将募集资金的约45%用于增强其国际及跨境物流能力。不难看出，H股上市，是顺丰控股全球化战略的重要一步，旨在利用全球资本，谋求更广阔的发展空间。从1到N 持续领跑行业发展自1993年公司创立以来顺丰控股于中国提供时效快递服务，以其创新的服务模式，在时效快递市场确立领先优势，树立了良好的品牌形象。依托在时效快递市场资源优势，公司不断捕捉客户日益变化的寄递需求，以边际成本孵化新业务，革新行业服务标准，将业务范围延伸至快运服务、冷运物流服务、同城即时配送服务、供应链服务及国际物流服务等领域，从中国辐射至亚洲乃至全球市场，成为一家全球领先的综合物流服务提供商，亦登榜《财富》世界500强企业。2024年获评《财富》最受赞赏的中国公司第二位，这也是顺丰连续8年上榜「《财富》最受赞赏的中国公司」。得益于业务范围拓宽和区域覆盖广度的提升，顺丰控股持续扩大其市场份额，并实现高于行业的增速，盈利能力持续增强。2021年至2023年，其收入增速及利润及息税折旧与摊销前利润增速均位列全球四大综合物流服务提供商第一。2024年前三季度，公司延续增长态势，收入同比增加9.4%，归母净利润同比增加21.6%。其中单三季度收入同比增加12.1%，归母净利润同比增加34.6%。值得一提的是，多重因素带动顺丰盈利强劲增长。公司经营现金流持续向好，并随着公司度过了资本支出的高峰期，自由现金流不断走强。2021年至2023年，公司自由现金流由负转正提升至144亿元。伴随规模经济效应、新业务盈利增长、成本结构及资产利用率优化，公司正步入高质量可持续发展轨道。抢滩国际市场 拓展业绩增量空间虽然当前国内快递市场增长速度开始放缓，但受中国企业出海、全球企业重塑供应链、以及跨境电商的推动，使得国际物流市场显示出强劲的增长动力。除中国地区外的亚洲市场，在区域内供应链重要性提升、跨境电商崛起、政策支持及贸易的共同驱动下，预计2023年至2028年物流支出复合年增长率将达到6.9%。此外，随着客户业务日趋复合多元化，领先的综合物流企业能够更好满足客户需求，在市场竞争中更具优势。面对市场机遇，顺丰控股近年来持续扩大物流网络，以抢占增长高地。公司运营亚洲最大的空运机队和陆运车队，并已开始运营鄂州货运枢纽的分拣及转运中心这一亚洲第一、全球第四座以货运为主的物流枢纽，以此进一步扩大国际网络覆盖能力，为国际物流服务提供有力支持。此外，顺丰控股还通过外延并购不断强化其国际物流服务能力。以2021年收购嘉里物流为例，此次收购不仅增强了其在东南亚本土及跨境快递、国际供应链和国际货代能力，还提升了其国际综合物流能力，扩大亚洲客户基础，进一步夯实其全球化发展的基础。通过香港上市，顺丰控股可藉助香港这一国际金融平台，吸引更多国际资本，提升其在国际市场的竞争力和品牌影响力，实现国际业务的加速拓展，释放长期投资价值。作为成长确定性较高的行业龙头，其未来发展值得期待。 Copyright 2024 亚太商讯 via SeaPRwire.com.